Navigation Links
Genesis Pharmaceuticals Affirms Operating Income Guidance, Adjusts Revenue Guidance for Fiscal 2009
Date:4/2/2009

at the medical community and end users. The Company's close relationship with a regional distributor recently led to expansion into Tibet. The Company hopes to continue geographical expansion and to gain greater market penetration through ongoing cooperation with regional distributors.

The Company has an internal marketing and sales network of 470 full time and 620 part time sales representatives who operate as local level marketers and product services personnel.

The Company's management believes that greater reliance on regional distributors will be needed in the future to support the Company's growing product portfolio.

"We are affirming our operating income guidance because of our positive view of the overall pharmaceutical market in China and our belief that restructuring our sales network will help us achieve our operating income goals," said Mr. Wubo Cao, Chief Executive Officer of Genesis. "As an important part of its medical reform initiatives, we understand that China plans to establish provincial and national basic medicine lists. We expect that most of our products will be on these national lists. We also expect to benefit from the Chinese government's plan to extend medical insurance coverage to a greater number of people. In addition, we hope that our close working relationships with local distributors will enable us to sell more of our products on a provincial level."

About Genesis Pharmaceuticals Enterprises, Inc.

Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule, gra
'/>"/>

SOURCE Genesis Pharmaceuticals Enterprises, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Cardiogenesis Reports Fourth Quarter and Fiscal Year 2008 Results
2. New Directions in Angioedema: A Focus on Pathogenesis and Classification
3. Angiogenesis inhibitor improves brain tumor survival by reducing edema
4. CFO of Genesis Pharmaceuticals Gives Live Interview on Bloomberg TV Asia
5. Cardiogenesis Corporation to Report 2008 Fourth Quarter and Year-End Results on March 31st
6. Study sheds light on angiogenesis inhibitors, points to limitations, solutions
7. Thermogenesis Technology Products Surpass Processing of More Than One Million Units of Cord Blood Stem Cells at 10-Year Milestone
8. Genesis Successfully Defends Multi-Million Dollar Arbitration Filed by CRG and CRGP; Related Parties Withdraw Remaining Demands for Arbitration Against Genesis
9. Genesis Pharmaceuticals Successfully Defends Itself in a Multi-Million Dollar Arbitration, Two Other Arbitration Proceedings Against Genesis are Withdrawn
10. Angiogenesis linked to poor survival in patients with rare type of ovarian cancer
11. Genesis Pharmaceuticals Enters Into Agreement to Purchase Hongrui Pharmaceuticals, and Acquire 22 New Traditional Chinese Medicines

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...sContinuetoTargetIndividualsintheRecommendedPriori...USNewswire/--TheDepartmentofHealthannouncedtodayth...atlocalStateHealthCentersinDelaware,Lancaster,andL...TheH1N1vaccinewillbeadministeredforfreetoindividua...usaccesstothevaccine.Thedepartmentasksthatonlyindi...
(Date:11/23/2009)...rs of cancer patients and survivors treated with c...t often become chronic conditions, hindering patie...ists at the University of Rochester Medical Center...xperienced sleep troubles at nearly three times th...more prevalent in younger patients and those with ...
(Date:11/23/2009)...v. 23, 2009) -- A first-of-its-kind consensus stat...y in the Annals of Surgery . The report illustrat...us conference -- Diabetes Surgery Summit (DSS) -- ...tific and medical experts agreed on a set of evide...t to guide the use and study of gastrointestinal s...
(Date:11/23/2009)...oubled number of patients who reined in their hype... 23 (HealthDay News) -- High blood pressure is bet...hand-in-hand than by doctors and pharmacists worki... work with pharmacists, medications are intensifie...ively," said Barry L. Carter, a professor in the U...
(Date:11/23/2009)...ershipswithMinorityBanksin Washington D.C. , .... IntendedtoSpurEconomicGrowthandRevitalization ...--DaVita,thenation,sleadingproviderofdialysisservi...acostiacommunityfora$1millioninvestmentinIndustria...ycommunities. ,, DaVita,sinvestmentinWashington...
Breaking Medicine News(10 mins):Health News:Pennsylvania Department of Health Announces Additional H1N1 Vaccination Clinics in Delaware, Lancaster, Lehigh Counties 2Health News:Insomnia prevalent among cancer patients who receive chemotherapy 2Health News:Diabetes surgery summit consensus lays foundation for new field of medicine 2Health News:Diabetes surgery summit consensus lays foundation for new field of medicine 3Health News:Diabetes surgery summit consensus lays foundation for new field of medicine 4Health News:Diabetes surgery summit consensus lays foundation for new field of medicine 5Health News:Doctor-Pharmacist Teams Boost Blood Pressure Control 2Health News:Doctor-Pharmacist Teams Boost Blood Pressure Control 3Health News:DaVita Launches Minority Bank Initiative with $1 Million Investment in Industrial Bank of Washington, D.C. to Support Underserved Communities 2Health News:DaVita Launches Minority Bank Initiative with $1 Million Investment in Industrial Bank of Washington, D.C. to Support Underserved Communities 3Health News:DaVita Launches Minority Bank Initiative with $1 Million Investment in Industrial Bank of Washington, D.C. to Support Underserved Communities 4
...er cells form by hijacking a developmental genetic...Scientists at the Georgia Institute of Technology ...he protein, PAX8, is involved in the development o...c and therapeutic interventions, but also opens ne...
...cereal-eating physicians taking part in the Physic...ngs// of wholegrain breakfast cereals reduced thei...research, presented last week at the American Hear...onsumption of wholegrain products to improvements ...
...er mental health conditions are potentially around...of Iowa study. The findings, which were based ...te blood cells, appear online March 6 in the Ameri...hilibert, M.D., Ph.D., professor of psychiatry in ...
...iversity of Leicester geologist was recently used ...m// Oversight Board to detect exposure of UK troop...nflict. Randall Parrish, Professor of Iso...t Horstwood at the British Geological Survey, usin...
...d that it may be possible to detect certain mental...tests//. This was revealed after scientists studie...cells. "The ability to test for panic disorde...A. Carver College of Medicine. "Panic disord...
...e under ongoing stress have more fevers with illne...t children’s natural killer cell function, part of...chronic stress, unlike adults, whose function is d...lth," said Mary Caserta, M.D., principal investiga...
Other Medicine News:Health News:Ovarian Cancer May Mimic Fallopian Tube Formation 2Health News:Ovarian Cancer May Mimic Fallopian Tube Formation 3Health News:Whole Grain Breakfasts Linked to Lower Heart Failure Risk 2Health News:Blood Tests may Be Possible for Mental Health Conditions 2Health News:DU Test Finds UK Troops Uranium Free 2Health News:Mental Health Conditions Could Be Detected With Blood Tests 2Health News:Children Under Stress Develop More Fevers 2
(Date:11/23/2009)..., WALTHAM,Mass.,Nov.23/PRNewswire/--ProteonThera...dyofitsleadproduct,PRT-201,inend-stagerenaldisease...ft(AVG)creation.TheAVGstudyrepresentsProteon,sseco...slyannouncingtheinitiationofaPhase1/2studyofPRT-20...stula(AVF)creationearlierthisyear.Proteonalsoannou...
(Date:11/23/2009)..., SOUTHSANFRANCISCO,Calif.,Nov.23/PRNewswire-Fir...thatDr.TedW.LoveandDr.DavidC.U,Prichardhaveagreedt...oftheproposedmergerbetweenAnesivaandArcionTherapeu...otescheduledtotakeplaceatthepreviouslyannouncedAne...mber3,2009at9:00a.m.PSTat400OysterPoint,Suite107A,...
(Date:11/23/2009)..., NOVATO,Calif.,Nov.23/PRNewswire-FirstCall/--Ra...sdaq: RPTP ),todayannouncedresultsfromaPhase2bclin...bitartrate("DRCysteamine")inpatientswithnephropath...UniversityofCalifornia,SanDiego("UCSD")GeneralClin...armacokineticsandpharmacodynamicsofasingledoseofDR...
Breaking Medicine Technology:Proteon Initiates Second Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 3Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 2Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 3Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 4Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 5OH2 Medical Spa Achieves the First U S LEED 28R 29 Certification for a Medical Commercial Interior 51691 1OH2 Medical Spa Achieves the First U S LEED 28R 29 Certification for a Medical Commercial Interior 51691 2Leading Blood Centers LifeSource and Central Blood Bank Spotlight a Unique Donor Population During National Hereditary Hemochromatosis Awareness Mon 51690 1Leading Blood Centers LifeSource and Central Blood Bank Spotlight a Unique Donor Population During National Hereditary Hemochromatosis Awareness Mon 51690 2Leading Blood Centers LifeSource and Central Blood Bank Spotlight a Unique Donor Population During National Hereditary Hemochromatosis Awareness Mon 51690 3Leading Blood Centers LifeSource and Central Blood Bank Spotlight a Unique Donor Population During National Hereditary Hemochromatosis Awareness Mon 51690 4Leading Blood Centers LifeSource and Central Blood Bank Spotlight a Unique Donor Population During National Hereditary Hemochromatosis Awareness Mon 51690 5Walking Biking to Work Pays Off 51688 1Walking Biking to Work Pays Off 51688 2
... /PRNewswire/ -- Results from,the primary analysis...study showed that 77 percent of treatment-experien...unavir) 600 mg tablets with,100 mg ritonavir (PREZ...regimen (OBR) of antiretroviral (ARV) agents, reac...48, compared to 68,percent of patients taking Kale...
...al in non-small cell lung cancer -, LOS ANGELES, J...netics, Inc. today announced that positive Phase I...the Journal of Clinical,Oncology suggests that low...-Complementing 1 (ERCC-1) in patient biopsies,with...cts for,sensitivity to cisplatin-based chemotherap...
Other Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 2Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 3Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 4
BioPette E Electronic Pipettor, 10-200l
Finnpipette BioControl Single Channel, 40-200ul
...or all liquid handling applications in the laborat...ced operating buttons, and various dispensing tech...tting and diluting make this a lab favorite. It in... pipette without any adverse effects on the variet...
... high performance electronic pipetting! , Soft, ...reduce hand fatigue and strain, Stress-free tip ...ing for easy volume identification, Accepts univ... AdvanTip Low Retention and AdvanTip Precision Pip...
Medicine Products: